#Switzerland #Heart Failure #Zug #Berlin Heals #Eric Fain

Berlin Heals Welcomes Dr. Eric Fain to Board of Directors

Berlin Heals Holding AG, a prominent player in the clinical-stage medical device industry, has announced the recent appointment of Dr. Eric S. Fain to its Board of Directors. This strategic addition is anticipated to significantly bolster the company's mission to transform the treatment landscape for chronic heart failure. With over 35 years of profound knowledge and experience in this field, Dr. Fain brings a wealth of expertise essential for the development of new therapeutic strategies.

Expanding Opportunities in Heart Failure Treatment

Dr. Fain's arrival comes at a crucial juncture for Berlin Heals, as the company prepares to unveil a less invasive design that stands to increase the patient demographic eligible for its groundbreaking C-MIC therapy. This device-based treatment aims to restore cardiac function and improve the quality of life for patients grappling with chronic heart failure. Dr. Fain expressed his enthusiasm, stating, "Developing technology to treat heart failure is a true passion of mine, and I am honored to join Berlin Heals at such a pivotal moment in the company's development."

As a physician and medtech executive, Dr. Fain boasts a distinguished background, having served in leadership roles at notable companies such as St. Jude Medical and Abbott. His contributions have included overseeing global operations in research, development, and commercialization of innovative implantable cardiac devices.

A Track Record of Success

Roland Diggelmann, a board member at Berlin Heals, highlighted Dr. Fain's extensive experience in the clinical and commercial aspects of cardiovascular innovation, pointing out his impressive history of developing and launching transformative technologies. "His proven track record combined with his drive and integrity will make him an exceptional addition to the team as we embark on our next growth phase," he remarked. Dr. Fain also serves as President and CEO of Procyrion, Inc., alongside being involved with various medical device companies.

Marko Bagaric, another board member and Co-Founder of Berlin Heals, reiterated the excitement surrounding Dr. Fain's appointment. He stated, "We are delighted to welcome Dr. Fain to our Board of Directors. His extensive experience in cardiovascular device innovation will be of tremendous value as we advance our C-MIC technology toward market introduction."

The Revolutionary C-MIC Therapy

C-MIC (Cardiac Microcurrent) therapy represents a significant advancement in the treatment of heart failure. Delivered through a fully implantable medical device, it uses two electrodes connected to an implantable generator to deliver a steady direct microcurrent to the affected heart. This continuous DC current aims to diminish inflammation and promote the heart’s remodeling process, which research has shown to enhance cardiac function and alleviate symptoms.

In its initial generation, deployment required a minimally invasive surgical procedure where a surgeon placed an electrode on the heart's exterior. However, Berlin Heals' new design allows for this procedure to occur in a cardiac catheterization lab, minimizing patient recovery time and paving the way for same-day discharge. This paradigm shift could drastically increase the patient pool able to benefit from C-MIC therapy.

Addressing the Heart Failure Crisis

Heart failure is a debilitating condition that weakens the heart, limiting its ability to meet the body's blood flow requirements. Symptoms can range from breathlessness and fatigue to severe palpitations, drastically affecting daily living. Currently, heart failure is estimated to affect over 64 million individuals globally, and its treatment poses a formidable economic burden with annual costs reaching $287 billion in the U.S. alone.

Sadly, this progressive disease often results in high rates of hospitalization and reduced quality of life, with few viable treatments available. Hence, the innovation that Berlin Heals seeks to introduce could not only improve patient outcomes but also potentially redefine the standard of care in managing this chronic condition.

Future Endeavors

As Berlin Heals looks toward the future, planning is underway for U.S. clinical studies and potential FDA approval submission. Dr. Fain’s insights and leadership will be pivotal in steering the company towards achieving these ambitious goals. By harnessing innovative technologies like C-MIC, Berlin Heals aims to make a significant impact in the fight against heart failure, propelling a new era of treatment that could enhance the lives of millions suffering from this challenging condition.

In conclusion, the addition of Dr. Eric Fain to the Berlin Heals Board marks a significant step forward in the quest to combat chronic heart failure. With his expertise and the company's visionary technology, the path forward is charged with hope and promise.